London-based pharmaceutical company AstraZeneca revealed that it began late stage trials for its investigative MEK inhibitor selumetinib to test its effectiveness as a potential treatment for non-small-cell lung cancer.
The company will enroll 634 NSCLC patients in the SELECT-1 (SELumetinib Evaluation as Combination Therapy-1) study. The study aims to compare the safety and efficacy of selumetinib in combination with Taxotere (Sanofi's version of docetaxel) to Taxotere and placebo. Progression free survival (PFS) and overall survival will be the main parameters in the study.
Lung Cancer Screening
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can help in early detection of cancer and possible cure.
Advertisement
AZ has taken this step following encouraging results from phase II trials, where selumetinib plus Taxotere resulted in progression free survival of 5.3 months versus 2.1 months in the Taxotere alone arm.
Source: Medindia
Lung Biopsy
The procedure by which tissue samples are obtained from the lung is known as lung biopsy. The biopsy tissues obtained from the lungs are examined by a pathologist.
Advertisement
Advertisement
|
Advertisement
